| Noninvasive nanoparticle strategies for brain tumor targeting C Sun, Y Ding, L Zhou, D Shi, L Sun, TJ Webster, Y Shen Nanomedicine: Nanotechnology, Biology and Medicine 13 (8), 2605-2621, 2017 | 87 | 2017 |
| A randomized, open-label, presurgical, window-of-opportunity study comparing the pharmacodynamic effects of the novel oral SERD AZD9496 with fulvestrant in patients with newly … JFR Robertson, A Evans, S Henschen, CC Kirwan, A Jahan, LM Kenny, ... Clinical Cancer Research 26 (16), 4242-4249, 2020 | 37 | 2020 |
| Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based … L Zhou, P Sharma, KR Yeo, M Higashimori, H Xu, N Al-Huniti, D Zhou European Journal of Pharmaceutical Sciences 139, 105061, 2019 | 34 | 2019 |
| Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study L Zhou, X Tong, P Sharma, H Xu, N Al‐Huniti, D Zhou Basic & clinical pharmacology & toxicology 125 (2), 100-107, 2019 | 21 | 2019 |
| Size-based anti-tumoral effect of paclitaxel loaded albumin microparticle dry powders for inhalation to treat metastatic lung cancer in a mouse model B Chaurasiya, L Huang, Y Du, B Tang, Z Qiu, L Zhou, J Tu, C Sun International journal of pharmaceutics 542 (1-2), 90-99, 2018 | 19 | 2018 |
| Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform … S Schalkwijk, L Zhou, S Cohen‐Rabbie, L Jain, T Freshwater, K So, Z He, ... Cancer Chemotherapy and Pharmacology 88 (2), 189-202, 2021 | 14 | 2021 |
| Physiologically based pharmacokinetic modeling for selumetinib to evaluate drug‐drug interactions and pediatric dose regimens S Cohen‐Rabbie, L Zhou, K Vishwanathan, M Wild, S Xu, T Freshwater, ... The Journal of Clinical Pharmacology 61 (11), 1493-1504, 2021 | 11 | 2021 |
| Biodistribution, activation, and retention of proinsulin-transferrin fusion protein in the liver: mechanism of liver-targeting as an insulin prodrug Y Liu, HY Wang, L Zhou, Y Su, WC Shen Journal of controlled release 275, 186-191, 2018 | 11 | 2018 |
| Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study F Meric-Bernstam, E Calvo, KS Lee, V Moreno, YH Park, SY Rha, ... Molecular Cancer Therapeutics, 2023 | 9 | 2023 |
| Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery L Zhou, HY Wang, S Tong, CT Okamoto, WC Shen, JL Zaro Biomaterials 117, 24-31, 2017 | 9 | 2017 |
| Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies. L Zhou, H Xu, N Al‐Huniti, D Zhou, M Higashimori, M Horiuchi, K Ichikawa, ... Clinical Pharmacology & Therapeutics 105 (6), 2019 | 8 | 2019 |
| Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes M Nagase, H Shimada, M Nii, S Ueda, M Higashimori, K Ichikawa, ... Journal of Clinical Pharmacy and Therapeutics 45 (5), 1030-1038, 2020 | 7 | 2020 |
| Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy B Chen, D Zhou, H Wei, M Yotvat, L Zhou, J Cheung, N Sarvaria, R Lai, ... British Journal of Clinical Pharmacology 88 (8), 3716-3729, 2022 | 6 | 2022 |
| Oncology Combination Dose‐Finding Study Design for Targeted and Immuno‐Oncology Therapies L Zhou, MB Reddy, RK Mittapalli, J Yang, D Yin Clinical Pharmacology & Therapeutics 115 (1), 29-35, 2024 | 1 | 2024 |
